Dong-A ST said it signed a global licensing agreement with NeuroBo Pharmaceuticals, a U.S. pharmaceutical company.Under the accord, Dong-A ST plans to accelerate the global development and commercialization of DA-1241, a type 2 diabetes and nonalcoholic steatohepatitis (NASH) treatment, and DA-1726,
Daehwa Pharmaceutical said Wednesday that it had been notified of the acceptance of the application for new drug approval for Liporaxel/RMX3001, oral paclitaxel (DHP107/RMX3001) drug, from China’s National Medical Products Administration.The indication of Liporaxel/RMX3001 seeking the Chinese permit
Lilly Korea said it released Retevmo (selpercatinib), the first RET (rearranged during transfection) targeted therapy, in Korea on Wednesday.The market release follows Retevmo’s winning the regulatory nod in March to treat adult patients with metastatic RET fusion-positive non-small cell lung cancer
The Ministry of Food and Drug Safety has added tumor lysis syndrome (TLS) to the adverse effects of sorafenib-based treatments for liver cancer.On Tuesday, the Drug Safety Assessment Division of the ministry made public changes in permitted contents – directions for use of medicine – of sorafenib dr
Qurient said it entered into a joint development agreement with MSD (Merck in the U.S.) for clinical research on the combination therapy of Q901, a selective CDK7 inhibitor, and MSD’s Keytruda, an anti-programmed cell death protein1 (PD-1) immunotherapy.Under the accord, the two companies will condu
MedPacto said Tuesday that it has presented a poster study on the interim clinical data of the Vactosertib combination therapy related to pancreatic cancer during the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer.The study is an investigator-initiated clinic
The Ministry of Food and Drug Safety imposed a three-month manufacturing suspension on two nutritional injection products of Samsung Pharm, GC Wellbeing Amino Inj. And GC WellBbing Neuramin Inc., last Thursday.The reason for the disposition is the “violation of the regulations on management responsi
Dx&Vx said it succeeded in raising 17.8 billion won ($12.9 million) by issuing convertible bonds (CB).According to the company, it will use the new fund for operating use and acquiring shares of other corporations. DA 1st Company Limited, a special purpose company, will acquire all CBs.The maturity
It has become almost certain that the government would cancel the licenses of all brain function-improving drugs using acetyl-L-carnitine as the main ingredient.Faced with a crisis of losing the annual 50 billion won (36.2 million) prescription market, domestic drugmakers called for the Ministry of
A year has passed since Organon & Co. spun off from MSD, vowing to be a company specializing in the field of female healthcare.Over the past year, Organon has made positive efforts to promote female health. For instance, it acquired companies producing postpartum solutions to treat postpartum hyster
Yuyu Pharmaceutical said it launched Senuvela, a treatment for hyperphosphatemia containing Sevelamer.Senuvela can control serum phosphorus in patients with chronic kidney disease (CKD) who do not have sufficient phosphorus excretion through diet and dialysis alone.With the launch of Senuvela, Yuyu
Hanmi Pharm and Seoul National University (SNU) have decided to collaborate to create a hub to foster global bio-industry talents. Hanmi said the company and SNU signed a memorandum of understanding to cooperate on building a global hub to cultivate a bio workforce as part of the World Health Organi
Daewoong Pharmaceutical has won the approval for a phase 2 investigational new drug (IND) clinical trial of DWN12088, its treatment candidate for idiopathic pulmonary fibrosis (IPF), in Korea following the nod in the U.S.The Ministry of Food and Drug Safety gave the go-ahead to Daewoong’s treatment
Allergan Aesthetics Korea said it has identified four key themes that will drive consumer behavior change in the global aesthetics market. The four key themes are beauty empowerment, aesthetic fluency, untabooing treatments, and a desire to move back to nature.The company has published the four them
Boryung said it obtained local marketing approval for finasteride-containing spray treatment for hair loss. Attention is on whether the new product could enlarge its presence in the hair loss treatment market dominated by MSD’s Propecia tablet. On Tuesday, the Ministry of Food and Drug Safety author
The European Medicines Agency (EMA) refused a rolling review of SK Bioscience’s Covid-19 vaccine, SKYCovine, due to “changing pandemic conditions,” a senior official at SK Bioscience said.A rolling review speeds up the evaluation of a drug or a vaccine during a public health crisis.The SK Bioscience
The growth of Alvogen Korea's obesity treatment Qsymia, which had been competing for a top market share with Novo Nordisk's Saxenda, is slowing down.Industry watchers attribute the relatively weaker performance of Qsymia to the absence of indications for obese adolescents aged 12 or older.Saxenda ob
The drug regulator ordered Korea Pharma to suspend manufacturing of medicines including steroid cream, saying the drugmaker violated the Good Manufacturing Practices (GMP). On Aug. 30, the Ministry of Food and Drug Safety ordered Korea Pharma’s manufacturing suspension due to the company’s violation
LG Chem is accelerating efforts to develop a new gout treatment.The company recently submitted applications for phase 3 investigational new drug (IND) clinical trials to the Chinese regulator, following the U.S., drawing attention to its future development process.In a public notice on Monday, LG Ch
Bridge Biotherapeutics said that it signed a cooperation agreement with Brainomix, a U.K.-based artificial intelligence (AI) medtech firm, to efficiently conduct phase 2 clinical trials of BBT-877, an idiopathic pulmonary fibrosis (IPF) treatment candidate.Under the accord, Bridge Biotherapeutics wi